Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report ; volume:3 ; number:1 ; day:27 ; month:8 ; year:2009 ; pages:1-3 ; date:12.2009
Journal of medical case reports ; 3, Heft 1 (27.8.2009), 1-3, 12.2009
- Creator
-
Gatzonis, Stylianos
- Contributor
-
Siatouni, Anna
SpringerLink (Online service)
- DOI
-
10.4076/1752-1947-3-8955
- URN
-
urn:nbn:de:1111-201607109783
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gatzonis, Stylianos
- Siatouni, Anna
- SpringerLink (Online service)
Other Objects (12)
Relapsing/remitting type 1 diabetes
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Postural Control in Relapsing-Remitting Multiple Sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Relapsing/remitting type 1 diabetes
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Postural Control in Relapsing-Remitting Multiple Sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Relapsing/remitting type 1 diabetes
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Postural Control in Relapsing-Remitting Multiple Sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis